BGI Genomics(SZ:300676)2022-04-22 16:00Financial Performance - Shenzhen BGI Genomics reported a revenue of 5.2 billion RMB in 2021, representing a year-over-year growth of 15%[7]. - The company achieved a net profit of 1.1 billion RMB, with a profit margin of approximately 21%[8]. - The company reported a significant increase in revenue, with a year-over-year growth of 25% in 2021[9]. - The company reported a total revenue of RMB 1.5 billion for the year 2021, representing a year-over-year increase of 20% compared to 2020[12]. - The company's operating revenue for 2021 was ¥6,766,137,315.11, a decrease of 19.42% compared to ¥8,397,230,002.83 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥1,461,536,272.38, down 30.08% from ¥2,090,285,273.48 in 2020[19]. - The net profit after deducting non-recurring gains and losses was ¥1,358,342,523.98, a decline of 33.71% compared to ¥2,049,045,082.77 in 2020[19]. - The total assets at the end of 2021 were ¥14,254,029,629.93, an increase of 27.32% from ¥11,195,040,535.59 at the end of 2020[19]. - The basic earnings per share for 2021 were ¥3.5643, down 32.13% from ¥5.2520 in 2020[19]. - The diluted earnings per share for 2021 were ¥3.5502, a decrease of 32.19% compared to ¥5.2353 in 2020[19]. - The weighted average return on equity for 2021 was 17.31%, down 23.13% from 40.44% in 2020[19]. - The company achieved a total revenue of 676,613.73 million CNY, a year-on-year decrease of 19.42%[95]. - The genomics application industry accounted for ¥6.75 billion, representing 99.83% of total revenue, with a year-on-year decrease of 19.47%[145]. - Revenue from infection prevention research and clinical application services increased by 73.01% to ¥1.16 billion, making up 17.12% of total revenue[146]. - The precision medicine testing comprehensive solution revenue decreased by 39.20% to ¥3.38 billion, which constituted 49.99% of total revenue[146]. Market Expansion and Strategy - BGI plans to expand its market presence in Europe and North America, targeting a 30% increase in international sales by 2023[8]. - The company is expanding its market presence in Europe, targeting a 15% market share by the end of 2022[9]. - The company has established partnerships with over 3,000 overseas medical and research institutions, enhancing its global reach and collaboration[40]. - The company has established a comprehensive marketing service network covering over 100 countries and all provinces in China, positioning itself as a leading technology service provider in the genomics industry[55]. - The company is focusing on expanding its market presence through innovative product development and strategic partnerships[65]. - The company is positioned to benefit from the growing market for synthetic biology, with increasing demand for oligonucleotide and gene synthesis driven by the COVID-19 pandemic[89]. - The company is actively promoting advanced gene technology applications in Belt and Road countries, enhancing local healthcare ecosystems[140]. Research and Development - The company is investing 500 million RMB in R&D for new genomic sequencing technologies, aiming to launch two new products in 2022[7]. - The company is investing in research and development, allocating 10% of its revenue towards innovative technologies[9]. - Research and development expenses increased by 15% to RMB 300 million, reflecting the company's commitment to innovation and new technology development[12]. - The company has established a strong data accumulation process in its research and industrialization efforts, utilizing multi-dimensional technologies for comprehensive disease understanding[77]. - The company has successfully optimized exosome separation technology for high-throughput and specific quantitative analysis of exosome proteomics[167]. - The company has developed a targeted metabolomics product capable of detecting over 300 gut microbiome metabolites, which has been officially launched[167]. - The company has developed a new technology platform that integrates standardized, automated, and information-based solutions for public health emergencies[94]. - The company has established a reproductive genetic database, focusing on genetic disease data to improve product performance and reduce costs[160]. Product Development and Innovation - BGI's new automated gene analysis system, HALOS, is anticipated to reduce processing time by 40%[8]. - The introduction of a new prenatal screening test is anticipated to capture a significant share of the market, estimated at $100 million annually[10]. - The company launched the HM350 product, which can detect over 350 human metabolites, enhancing its product portfolio in metabolic testing[13]. - The company has developed a comprehensive solution for infectious disease diagnosis and treatment, utilizing PMseq for precise pathogen diagnosis and monitoring antimicrobial drug concentrations throughout treatment[137]. - The company has developed a comprehensive maternal and child health management platform, covering over 13 million screening instances across more than 20 provinces in China[107]. - The company has launched multiple new testing kits, including those for COVID-19 variants and carbapenem-resistant gene detection, achieving CE certification for several products[104]. - The company has developed a comprehensive pathogen database to support its PMseq® product line, enhancing its capabilities in pathogen identification and international business expansion[136]. - The company has developed a closed-loop product line for tumor gene detection across prevention, early screening, diagnosis, and monitoring, significantly enhancing its influence in the tumor prevention and control sector[135]. Operational Efficiency - The company aims to improve operational efficiency, targeting a 5% reduction in costs through automation[9]. - The company has established a comprehensive information management system to enhance data analysis and processing capabilities, supporting digital transformation across all business processes[128]. - The company has achieved a significant increase in detection throughput for non-invasive colorectal cancer testing through automation, enhancing service quality for public health[92]. - The company has established a fully automated NIPT testing platform capable of processing over one million samples, improving delivery efficiency for large-scale projects[112]. Partnerships and Collaborations - The company has established partnerships with over 280 hospitals domestically, equipped with nearly 500 domestic sequencing platforms, enhancing its market presence[89]. - The company has collaborated with over 500 top-tier hospitals for cancer prevention and control, providing genetic testing services to more than 150,000 individuals[101]. - The company has established strategic partnerships with leading hospitals, including Zhongshan Hospital affiliated with Fudan University, to enhance collaborative research and clinical applications[125]. - The company has initiated a collaboration with AstraZeneca for the promotion of HRD companion diagnostic kits, enhancing the accessibility of HRD testing in China[103]. Regulatory Compliance and Certifications - The company has obtained EU CE certification for various testing kits, including multi-detection and rapid nucleic acid testing products[97]. - The IVD factory in Ethiopia received ISO 13485 certification, marking it as the first IVD enterprise in Ethiopia to achieve this certification[97]. - The company has received 199 medical device registration certificates from the National Medical Products Administration, with 113 overseas certifications, including 71 EU CE IVD certifications[114]. - The company has achieved CE certification for its BRCA1/2 gene mutation detection kit and related software, ensuring comprehensive EU regulatory compliance for its BRCA testing[134]. Public Health Initiatives - The company has provided genetic screening services for over 1 million newborns and adults for hereditary hearing loss, identifying thousands of affected individuals and offering early treatment opportunities[100]. - The company has launched cancer prevention initiatives benefiting over 53,000 people, promoting early screening and diagnosis through various public health campaigns[119]. - The company is committed to leveraging advancements in gene technology to benefit public health and enhance service accessibility[47]. - The company has implemented a cancer prevention information platform that has improved screening rates and follow-up rates for cancer patients, exceeding national averages[107].